New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers fro...

The PARP inhibitor Lynparza is in a three-way market battle with GSK's Zejula and Clovis' Rubraca. (AstraZeneca) In the red-hot market for PARP inhibitors, Astra...

(Credit: AstraZeneca ) Adding AstraZeneca's Lynparza to Roche's older cancer drug Avastin helped women with advanced ovarian cancer live longer without their tum...

Zolgensma won FDA approval in May as the drugmaker was working on an internal probe over data manipulation. (Novartis) Amid a fresh scandal, this time over data ...